Mizuho Raises LivaNova (NASDAQ:LIVN) Price Target to $90.00

LivaNova (NASDAQ:LIVN) had its target price lifted by stock analysts at Mizuho from $85.00 to $90.00 in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price target would indicate a potential upside of 25.24% from the company’s previous close.

LIVN has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. Barclays raised their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research note on Wednesday, February 25th. Finally, Robert W. Baird reduced their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus price target of $77.22.

LivaNova Stock Performance

NASDAQ:LIVN opened at $71.86 on Thursday. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $72.51. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.16 and a current ratio of 1.33. The company has a 50 day moving average price of $64.01 and a 200 day moving average price of $62.15. The stock has a market capitalization of $3.95 billion, a P/E ratio of 36.85 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the previous year, the company earned $0.88 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts forecast that LivaNova will post 3.66 EPS for the current year.

Institutional Trading of LivaNova

Several hedge funds have recently modified their holdings of LIVN. Artisan Partners Limited Partnership boosted its holdings in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares during the period. Wellington Management Group LLP increased its holdings in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the period. Invesco Ltd. raised its position in LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after purchasing an additional 902,447 shares in the last quarter. Scopia Capital Management LP acquired a new stake in LivaNova in the 2nd quarter valued at about $36,657,000. Finally, Millennium Management LLC boosted its stake in shares of LivaNova by 22.4% in the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after buying an additional 544,033 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.